February 28, 2015 11:09 AM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

105 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 65
Total Annual Compensation: $525.0K
Chief Business Officer, Senior Vice President and Director
Age: 45
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Age: 56
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:25 AM

Five Prime Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:25 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.

Five Prime Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:30 AM

Five Prime Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.

Five Prime Mulls Acquisitions

Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is looking for acquisitions. Five Prime Therapeutics, Inc. has filed a follow-on equity offering in the amount of $75 million and intend to use the net proceeds from the sale for the licensing or acquisition of, or the development of, additional product candidates, technologies, compounds, other assets or complementary businesses and to invest in interest-bearing, investment-grade securities.

Similar Private Companies By Industry

Company Name Region
Avaxia Biologics, Inc. United States
Molecular Imaging Products Company United States
Ginkgo BioWorks, Inc. United States
MyGene International Inc. United States
Nano3D Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 19, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.